Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma

NCT01403636 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01403636
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01403636 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of SAR245409 in Patients With Relapsed or Refractory Mantle Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Diffuse Large B Cell Lymphoma
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
September 30, 2014
Enrollment
167 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma